Publication: 2794

Publication: 2794

A non-comparative multi-center randomized phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Lancet Oncol vol 19 (3) 416-426

Year:: 2018
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:: http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(18)30006-8.pdf

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 7

Parents:: 2678
Children:: None

Program:: OGC
Primary Committee:: Experimental
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, U10CA041287, U10CA045808, U10CA047642, U10CA077440, U10CA007968, U10CA077651, U10CA180791, U10CA180833, U10CA180836, UG1CA189858

Corr. Author:
Authors:: Sandra P. D'Angelo Michelle R. Mahoney Brian A. Van Tine James Atkins Mohammed M. Milhem Balkrishna N. Jahagirdar Cristina R. Antonescu Elise Horvath William D. Tap Gary K. Schwartz Howard Streicher

Networks:: COLUMBIA, IA018, LAPS-MN026, LAPS-MO011, LAPS-NY016, METROMIN, NC002

Study: Alliance-A091401
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: